$CELG Company News Celgene revenue rises on ca
Post# of 74550
Posted On: 01/31/2015 11:02:32 AM
$CELG Company News
Celgene revenue rises on cancer-drug sales 8:04 a.m. Jan. 29, 2015 - MarketWatch.com
Major U.S. benchmarks challenge last-ditch support 11:31 a.m. Jan. 20, 2015 - Michael Ashbaugh
Major U.S. benchmarks challenge last-ditch support 11:09 a.m. Jan. 20, 2015 - Michael Ashbaugh
Some of the Nasdaq’s leading lights have begun to dim 2:02 p.m. Jan. 15, 2015 - The Trading Deck
GameStop shares rally on strong holiday sales 5:48 p.m. Jan. 13, 2015 - MarketWatch
Celgene shares gain 3.6% to top S&P 500 9:40 a.m. Jan. 13, 2015 - Sue Chang
Three investments to own and three to 6:00 a.m. Jan. 13, 2015 - Howard Gold
Updates, advisories and surprises 12:31 p.m. Jan. 12, 2015 - MarketWatch
Celgene's 2015 profit outlook is below forecasts 12:18 p.m. Jan. 12, 2015 - MarketWatch.com
Celgene's stock rises, but off highs after profit outlook 11:48 a.m. Jan. 12, 2015 - Tomi Kilgore
Celgene's stock gains 1.2% after Q4 profit view tops expectations 11:26 a.m. Jan. 12, 2015 - Tomi Kilgore
Why speculators see opportunity in younger, cyclical stocks 2:50 p.m. Dec. 26, 2014 - The Trading Deck
GoPro, Gilead Sciences, Celgene gain 11:27 a.m. Dec. 26, 2014 - MarketWatch
Dow ekes out gain for 37th record close of 2014 2:55 p.m. Dec. 24, 2014 - Carla Mozee
GoPro, Adamas climb, Cal-Maine slides 10:06 a.m. Dec. 24, 2014 - MarketWatch
Cal-Maine Foods shares fall on earnings miss 4:41 p.m. Dec. 23, 2014 - Barbara Kollmeyer
A teachable moment: Here are my worst stock picks of 2014 10:19 a.m. Dec. 23, 2014 - Jeff Reeves
Four signs that would indicate a new uptrend 2:52 p.m. Dec. 16, 2014 - The Trading Deck
Liquid growth stocks tell interesting tale 3:10 p.m. Dec. 9, 2014 - The Trading Deck
H&R Block shares fall on quarterly miss 6:41 p.m. Dec. 8, 2014 - Sue Chang
Celldex/Bristol-Myers Initiate Phase I/II Solid Tumor Study - Analyst Blog 5:25 p.m. Jan. 30, 2015 - Zacks.com
Intercept Pharmaceuticals' OCA Now Breakthrough Therapy - Analyst Blog 4:54 p.m. Jan. 30, 2015 - Zacks.com
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More 4:00 p.m. Jan. 30, 2015 - Seeking Alpha
Update: Celgene Continues To Have A Large Gap In Its GAAP Reporting 1:28 p.m. Jan. 30, 2015 - Seeking Alpha
Regeneron Shows Biotech Investors Have Left Their Wildcatting Days 12:12 p.m. Jan. 30, 2015 - Seeking Alpha
Stocks That Battle Cancer Were The Best-Performing Biotechs In January 12:03 p.m. Jan. 30, 2015 - benzinga.com
Biogen Tops Q4 Earnings, Provides Strong Outlook for 2015 - Analyst Blog 11:40 a.m. Jan. 30, 2015 - Zacks.com
Celgene's EPS Contain 'Few Surprises,' Baird Says 11:05 a.m. Jan. 30, 2015 - benzinga.com
Eli Lilly's 4Q Earnings Beat, Revenue Outlook Lowered - Analyst Blog 10:54 a.m. Jan. 30, 2015 - Zacks.com
AbbVie Q4 Earnings Beat Expectations on Humira Strength - Analyst Blog 10:50 a.m. Jan. 30, 2015 - Zacks.com
SurModics Beats on Q1 Earnings, Reaffirms 2015 Guidance - Analyst Blog 10:20 a.m. Jan. 30, 2015 - Zacks.com
IBB Is +34% For 1 Year And +7.31% For 2015 - But What Are The Risks? 10:07 a.m. Jan. 30, 2015 - Seeking Alpha
Hottest Healthcare Stocks Now – BIIB LGND OPK CELG 6:00 a.m. Jan. 30, 2015 - InvestorPlace.com
Celgene's (CELG) CEO Bob Hugin on Q4 2014 Results - Earnings Call Transcript 7:39 p.m. Jan. 29, 2015 - Seeking Alpha
Celgene (CELG) Earnings Report: Q4 2014 Conference Call Transcript 5:28 p.m. Jan. 29, 2015 - TheStreet.com
Incyte's Phase III RESPONSE Data on Jakafi Published - Analyst Blog 4:35 p.m. Jan. 29, 2015 - Zacks.com
Alexion Misses on Q4 Earnings, 2015 Outlook Disappoints - Analyst Blog 4:20 p.m. Jan. 29, 2015 - Zacks.com
Salix Financial Results Need Correcting: Audit Committee - Analyst Blog 4:19 p.m. Jan. 29, 2015 - Zacks.com
BioDelivery Signs Agreement with Meda for Onsolis - Analyst Blog 4:07 p.m. Jan. 29, 2015 - Zacks.com
Alexion Beats Q4 Estimates, Appoints New CEO 12:28 p.m. Jan. 29, 2015 - Investors Business Daily
Celgene Corporation to Webcast at Upcoming Investor Conferences 8:30 a.m. Jan. 27, 2015 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment of Patients with Non-Small Cell Lung Cancer 7:19 a.m. Jan. 23, 2015 - BusinessWire - BZX
Critical Alerts For Apple, VoxelJet, Celgene, TASER International and Finisar Released By InvestorsObserver 9:31 a.m. Jan. 22, 2015 - PR Newswire - PRF
Insider Trading Buzz for Alcoa, Southwestern Energy, Celgene, Micron, FXCM, and Twitter 8:45 a.m. Jan. 21, 2015 - PR Newswire - PRF
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis 12:24 p.m. Jan. 16, 2015 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis 9:10 a.m. Jan. 16, 2015 - BusinessWire - BZX
Hogging the Limelight: New Research on Netlist, Celgene, Jamba, Citigroup and Tilly's 8:40 a.m. Jan. 14, 2015 - PR Newswire - PRF
Biotechs to Follow in 2015 off Fresh Insider Moves 10:00 a.m. Jan. 6, 2015 - ACCESSWIRE
Celgene Corporation to Present at the 33rd Annual J.P. Morgan Healthcare Conference 8:31 a.m. Jan. 6, 2015 - BusinessWire - BZX
Critical Alerts For Invensense, FireEye, General Electric, Twitter and Celgene Released By InvestorsObserver 9:31 a.m. Dec. 22, 2014 - PR Newswire - PRF
Scanning Biotech Equities -- Celgene, Novavax, Amarin, Immunomedics, and Aeterna Zentaris 8:40 a.m. Dec. 17, 2014 - PR Newswire - PRF
Data Presented on REVLIMID® (lenalidomide) Compared with Investigators’ Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma 8:34 p.m. Dec. 8, 2014 - BusinessWire - BZX
Additional Analyses of High-Risk Patients from Phase III Study (AML-001) OF Vidaza® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
REVLIMID® (Lenalidomide) Single-Agent and Combination Studies in Mantle Cell Lymphoma (MCL) Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition 2:00 p.m. Dec. 8, 2014 - BusinessWire - BZX
Results from Phase III Study of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented at ASH 1:49 p.m. Dec. 8, 2014 - BusinessWire - BZX
Age, Renal Impairment and Depth of Response Analyses of the FirstTM (MM-020/IFM 07-01)Study of Continuous REVLIMID® (lenalidomide) Plus Low-Dose dexamethasone in Newly-Diagnosed Multiple Myeloma Presented at ASH 9:58 p.m. Dec. 7, 2014 - BusinessWire - BZX
Critical Alerts For Noodles & Company, Goldcorp, YY, Celgene and LinkedIn Released By InvestorsObserver 9:31 a.m. Dec. 2, 2014 - PR Newswire - PRF
Celgene Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Corporation 4:30 p.m. Dec. 1, 2014 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis 6:00 a.m. Nov. 21, 2014 - BusinessWire - BZX
Celgene revenue rises on cancer-drug sales 8:04 a.m. Jan. 29, 2015 - MarketWatch.com
Major U.S. benchmarks challenge last-ditch support 11:31 a.m. Jan. 20, 2015 - Michael Ashbaugh
Major U.S. benchmarks challenge last-ditch support 11:09 a.m. Jan. 20, 2015 - Michael Ashbaugh
Some of the Nasdaq’s leading lights have begun to dim 2:02 p.m. Jan. 15, 2015 - The Trading Deck
GameStop shares rally on strong holiday sales 5:48 p.m. Jan. 13, 2015 - MarketWatch
Celgene shares gain 3.6% to top S&P 500 9:40 a.m. Jan. 13, 2015 - Sue Chang
Three investments to own and three to 6:00 a.m. Jan. 13, 2015 - Howard Gold
Updates, advisories and surprises 12:31 p.m. Jan. 12, 2015 - MarketWatch
Celgene's 2015 profit outlook is below forecasts 12:18 p.m. Jan. 12, 2015 - MarketWatch.com
Celgene's stock rises, but off highs after profit outlook 11:48 a.m. Jan. 12, 2015 - Tomi Kilgore
Celgene's stock gains 1.2% after Q4 profit view tops expectations 11:26 a.m. Jan. 12, 2015 - Tomi Kilgore
Why speculators see opportunity in younger, cyclical stocks 2:50 p.m. Dec. 26, 2014 - The Trading Deck
GoPro, Gilead Sciences, Celgene gain 11:27 a.m. Dec. 26, 2014 - MarketWatch
Dow ekes out gain for 37th record close of 2014 2:55 p.m. Dec. 24, 2014 - Carla Mozee
GoPro, Adamas climb, Cal-Maine slides 10:06 a.m. Dec. 24, 2014 - MarketWatch
Cal-Maine Foods shares fall on earnings miss 4:41 p.m. Dec. 23, 2014 - Barbara Kollmeyer
A teachable moment: Here are my worst stock picks of 2014 10:19 a.m. Dec. 23, 2014 - Jeff Reeves
Four signs that would indicate a new uptrend 2:52 p.m. Dec. 16, 2014 - The Trading Deck
Liquid growth stocks tell interesting tale 3:10 p.m. Dec. 9, 2014 - The Trading Deck
H&R Block shares fall on quarterly miss 6:41 p.m. Dec. 8, 2014 - Sue Chang
Celldex/Bristol-Myers Initiate Phase I/II Solid Tumor Study - Analyst Blog 5:25 p.m. Jan. 30, 2015 - Zacks.com
Intercept Pharmaceuticals' OCA Now Breakthrough Therapy - Analyst Blog 4:54 p.m. Jan. 30, 2015 - Zacks.com
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More 4:00 p.m. Jan. 30, 2015 - Seeking Alpha
Update: Celgene Continues To Have A Large Gap In Its GAAP Reporting 1:28 p.m. Jan. 30, 2015 - Seeking Alpha
Regeneron Shows Biotech Investors Have Left Their Wildcatting Days 12:12 p.m. Jan. 30, 2015 - Seeking Alpha
Stocks That Battle Cancer Were The Best-Performing Biotechs In January 12:03 p.m. Jan. 30, 2015 - benzinga.com
Biogen Tops Q4 Earnings, Provides Strong Outlook for 2015 - Analyst Blog 11:40 a.m. Jan. 30, 2015 - Zacks.com
Celgene's EPS Contain 'Few Surprises,' Baird Says 11:05 a.m. Jan. 30, 2015 - benzinga.com
Eli Lilly's 4Q Earnings Beat, Revenue Outlook Lowered - Analyst Blog 10:54 a.m. Jan. 30, 2015 - Zacks.com
AbbVie Q4 Earnings Beat Expectations on Humira Strength - Analyst Blog 10:50 a.m. Jan. 30, 2015 - Zacks.com
SurModics Beats on Q1 Earnings, Reaffirms 2015 Guidance - Analyst Blog 10:20 a.m. Jan. 30, 2015 - Zacks.com
IBB Is +34% For 1 Year And +7.31% For 2015 - But What Are The Risks? 10:07 a.m. Jan. 30, 2015 - Seeking Alpha
Hottest Healthcare Stocks Now – BIIB LGND OPK CELG 6:00 a.m. Jan. 30, 2015 - InvestorPlace.com
Celgene's (CELG) CEO Bob Hugin on Q4 2014 Results - Earnings Call Transcript 7:39 p.m. Jan. 29, 2015 - Seeking Alpha
Celgene (CELG) Earnings Report: Q4 2014 Conference Call Transcript 5:28 p.m. Jan. 29, 2015 - TheStreet.com
Incyte's Phase III RESPONSE Data on Jakafi Published - Analyst Blog 4:35 p.m. Jan. 29, 2015 - Zacks.com
Alexion Misses on Q4 Earnings, 2015 Outlook Disappoints - Analyst Blog 4:20 p.m. Jan. 29, 2015 - Zacks.com
Salix Financial Results Need Correcting: Audit Committee - Analyst Blog 4:19 p.m. Jan. 29, 2015 - Zacks.com
BioDelivery Signs Agreement with Meda for Onsolis - Analyst Blog 4:07 p.m. Jan. 29, 2015 - Zacks.com
Alexion Beats Q4 Estimates, Appoints New CEO 12:28 p.m. Jan. 29, 2015 - Investors Business Daily
Celgene Corporation to Webcast at Upcoming Investor Conferences 8:30 a.m. Jan. 27, 2015 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment of Patients with Non-Small Cell Lung Cancer 7:19 a.m. Jan. 23, 2015 - BusinessWire - BZX
Critical Alerts For Apple, VoxelJet, Celgene, TASER International and Finisar Released By InvestorsObserver 9:31 a.m. Jan. 22, 2015 - PR Newswire - PRF
Insider Trading Buzz for Alcoa, Southwestern Energy, Celgene, Micron, FXCM, and Twitter 8:45 a.m. Jan. 21, 2015 - PR Newswire - PRF
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis 12:24 p.m. Jan. 16, 2015 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis 9:10 a.m. Jan. 16, 2015 - BusinessWire - BZX
Hogging the Limelight: New Research on Netlist, Celgene, Jamba, Citigroup and Tilly's 8:40 a.m. Jan. 14, 2015 - PR Newswire - PRF
Biotechs to Follow in 2015 off Fresh Insider Moves 10:00 a.m. Jan. 6, 2015 - ACCESSWIRE
Celgene Corporation to Present at the 33rd Annual J.P. Morgan Healthcare Conference 8:31 a.m. Jan. 6, 2015 - BusinessWire - BZX
Critical Alerts For Invensense, FireEye, General Electric, Twitter and Celgene Released By InvestorsObserver 9:31 a.m. Dec. 22, 2014 - PR Newswire - PRF
Scanning Biotech Equities -- Celgene, Novavax, Amarin, Immunomedics, and Aeterna Zentaris 8:40 a.m. Dec. 17, 2014 - PR Newswire - PRF
Data Presented on REVLIMID® (lenalidomide) Compared with Investigators’ Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma 8:34 p.m. Dec. 8, 2014 - BusinessWire - BZX
Additional Analyses of High-Risk Patients from Phase III Study (AML-001) OF Vidaza® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
REVLIMID® (Lenalidomide) Single-Agent and Combination Studies in Mantle Cell Lymphoma (MCL) Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition 2:00 p.m. Dec. 8, 2014 - BusinessWire - BZX
Results from Phase III Study of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented at ASH 1:49 p.m. Dec. 8, 2014 - BusinessWire - BZX
Age, Renal Impairment and Depth of Response Analyses of the FirstTM (MM-020/IFM 07-01)Study of Continuous REVLIMID® (lenalidomide) Plus Low-Dose dexamethasone in Newly-Diagnosed Multiple Myeloma Presented at ASH 9:58 p.m. Dec. 7, 2014 - BusinessWire - BZX
Critical Alerts For Noodles & Company, Goldcorp, YY, Celgene and LinkedIn Released By InvestorsObserver 9:31 a.m. Dec. 2, 2014 - PR Newswire - PRF
Celgene Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Corporation 4:30 p.m. Dec. 1, 2014 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis 6:00 a.m. Nov. 21, 2014 - BusinessWire - BZX
(0)
(0)